«King of probiotics» Bacillus coagulans in modern combined probiotic preparations Laktovit forte (full review)
Keywords:
Bacillus coagulans, pharmacology, biological properties, biological activity, bacteriocins, reviewAbstract
Bacillus coagulans has an advantage over most other bacteria used as probiotics. It occupies an intermediate position between the genera Bacillusand Lactobacillus, is a spore-forming bacteria that produce lactic acid.This bacteria in the spores form can tolerate well technology processes, resistant to antibiotics and antiseptics, does not collapse under the influence of gastric juice and bile. Getting into the duodenum, the spores germinate into vegetative forms and begin vegetation and growth, providing probiotic effects. Bacillus coagulansrefers to semi-residental bacteria - performing in the human probiotic function, it passes the sporulation phase and slowly leaves the body, standing out in the faeces in the spores form. Thus, it does not violate the personal composition of intestinal microflora.Probiotic Bacillus coagulans enhances the microbiological composition of the intestine, increasing the number of obligate microorganisms and displacing pathogenic flora. Mechanisms of this action based on the lactic acid production and some bacteriocins synthesis, also on the immunomodulatory effect - stimulation of cellular and humoral immunity. The bacterial cell wall and spores are the main immunomodulatory compounds of the Bacillus coagulans.Apparently, namely Bacillus coagulans immunomodulatory properties play a crucial role in the pharmacological effects. It is now well known about the important role of immune system in the pathogenesis of many diseases; it has the clinical effect without the need for intensive growth of bacteria and intestinal colonization; even small amounts of spores are sufficient for pharmacological effect; many experimental evidences of the spore penetration into the lymphatic system and interaction with immunocompetent cells, as well as local and systemic immune effects of probiotic.In addition to this main action, Bacillus coagulans helps to digest lactose, possesses anti-inflammatory and antioxidant activity, as well as the cholesterol-lowering effect.The effectiveness of probiotics, containing spores of Bacillus coagulans, was confirmed by evidence-based medicine. Probiotic effect in the treatment of various diarrheas, including those related to antibiotic treatment, enterocolitis and irritable bowel syndrome. Bacillus coagulans application reduces the duration of diarrhea, reduces the severity of abdominal pain, and normalizes the composition of intestinal microflora.Bacillus coagulans efficiency is identified also as hypocholesterolemic agents, as a means of anti-inflammatory effect in the combination therapy of arthritis, in combination with soya extracts for reducing menopause symptoms; by topical application it was effective in vaginitis, stomatitis and dental caries. In clinical studies proved the high safety of probiotics. Except spores Bacillus coagulans, as part of the “Laktovit Forte” there are also present B9 and B12 vitamins in high doses, which are an essential component for the early spore’s vegetation in the large intestine. These vitamins stimulation phenomenon vegetation dispute has been confirmed experimentally, as shown in the clinic acceleration by 1-2 days of initial clinical manifestations of the effects of Bacillus coagulans, which is quite critical in acute diarrhea microbial origin, abdominal pain and cramps.
References
Casula G. Bacillus probiotics: spore germination in
the gastrointestinal tract [Text] / G. Casula , S. M. Cutting
// Appl Environ Microbiol.- 2002.- Vol.68, N 5.-
P.2344-2352.
Adami, A. Biomass production, preservation and
characteristics of a strain of Bacillus coagulans as probiotic[
Text]/ A.Adami, V. Cavazzoni // Microbiologie
Aliments Nutrition.-1993.- Vol. 11.- P. 93-100.
Snetah P H A, Mair N S, Sharpe M E, Holt J G
(EDS). Genus Bacillus Cohn 1872. [Text] // Bergey’s
Manual of Systematic Bacteriology (Baltimore: Williams
and Wilkins).- 1986.-1105 - Claus D, Berkeley R C W 39
Claus, D. and Berkeley, R.C.W. (1986). Genus
Bacillus Cohn 1872. In Snetah, P.H.A., Mair, N.S.,
Sharpe, M.E. and Holt, J.G. (EDS), Bergey’s Manual of
Systematic Bacteriology (Baltimore: Williams and Wilkins)
[Text] // pp.1105-1139.
FAO/WHO. Expert Consultation on Evaluation of
Health and Nutritional Properties of Probiotics in Food
including Powder Milk with Live Lactic Acid Bacteria
[Text] // Report 2001. FAO/WHO; Сordoba, Argentina:
Nakamura L K. Phylogeny of Bacillus sphaericus –
like organisms [Text]/ L. K. Nakamura // International
Journal of Systemic and Evolutionary Microbiology.-
-Vol.50.-P.1715-1722.
EverPup. Режим доступа:
http://www.everpup.co.uk/ingredients/probiotics-fromlactobacillus-
sporogenes/
Weese J.S. Microbiologic evaluation of commercial
products [Text]/ J. S. Weese // Journal of the American
Veterinary Medical Association.- 2002.-Vol. 220.- P.
-797.
De Vecchi E. Lactobacillus sporogenes or Bacillus
coagulans: misidentification or mislabelling? [Text]/ E.
De Vecchi, L. Drago //International Journal of Probiotics
and Prebiotics.- 2006.- Vol.1, N.1.- P.3-10.
Pat. US8697055 B2 US, Probiotic, lactic acidproducing
bacteria / Farmer Sean (Miami, FL); FARMER
SEAN [US]; GANEDEN BIOTECH INC [US]. – US
/423,852; Filed: March 19, 2012; Date of Patent Apr.
, 2014.
Abdhul K. Bacteriocinogenic potential of a probiotic
strain Bacillus coagulans [BDU3] from Ngari [Text] /
Abdhul K., M. Ganesh, S. Shanmughapriya, et al.//
IntJBiolMacromol.- 2015.-Vol. 79.-P.: 800-806.
Hyronimus B. Acid and bile tolerance of sporeforming
lactic acid bacteria [Text] / B. Hyronimus, C. Le
Marrec, A. H. Sassi, A. Deschamps // International Journal
of Food Microbiology.- 2000.-Vol.61, N 1-2.-P.193-
Lactobacillus sporogenes improves gastrointestinal
ecology // Alternative Medicine Review, August, 2002.
Режим доступа: http://forums.prohealth.com/ forums/
index.php?threads/ lactobacillus-sporogenesimproves-
gastrointestinal-ecology.131865/
Chateau N.Heterogeneity of bile salts resistance in
the Lactobacillus isolates of a probiotic consortium [Text]
/ N.Chateau, A.M. Deschamps, A. Hadj Sassi // Letts
Appl Microbiol.-1994.-Vol.18.-P.42–44.
Jacobsen C.N.Screening of probiotic activities of
forty-seven strains of Lactobacillus spp. by in vitro techniques
and evaluation of the colonization ability of five
selected strains in humans [Text] / C.N.Jacob-sen, Rosenfeldt
Nielsen V., A.E. Hayford, et al. // Appl Environ
Microbiol.-1999.-Vol. 65.-P. 4949–4956.
Zarate G.Effect of bile on the β-galactosidase activity
of dairy propionibacteria [Text]/G. Zarate, S. Gonzalez,
A.P. Chaia, G. Oliver // Lait.-2000.-Vol.80.- P.267–
Ibrahim S.A. Survival of bifidobacteria in the presence
of bile salt [Text]/ S.A.Ibrahim, A. Bezhorovainy // J
Sci Food Agric.-1993.-Vol. 62.-P.351–354.
Clark P.A., Martin J.H. Selection of bifidobacteria
for use as dietary adjuncts in cultured dairy foods. III.
Tolerance to simulated bile concentrations of human
small intestines[Text]/ P.A.Clark, J.H. Martin // Cult
Dairy Prod J.-1994.-Vol.29.- P.18–21.
Hong H. A. The use of bacterial spore formers as
probiotics [Text]/H. A. Hong, L.H. Duc, S. M.Cutting //
FEMS Microbiology Reviews.- 2005.- Vol.29, N.4.-
P.813-835.
Amaha M., Ordal Z.J., Touba A. Sporulation requirements
of Bacillus coagulans var. Thermoacidurans in
complex media / M. Amaha, Z.J.Ordal, A. Touba // J
Bacteriol.- 1956.- Vol.72, N1.- P.34–41.
Palestrant D. Microbial biofilms in the gut: visulalization
by electron microscopy and by acridine orange
staining [Text] / D. Palestrant, Z. E. Holzknecht, B.
H. Collins, et al. // Ultrastruct Pathol.-2004.-Vol.28.-
Р.23–27.
Mendelson N.H. Bacillus subtilis macrofibres, colonies
and bioconvection patterns use different strategies
to achieve multicellular organization [Text] / N.H. Mendelson
// Environ Micribiol.-1999. .-Vol.1.-P.471–477.
Rajagopalan S. Modeling substrate particle degradation
by Bacillus coagulans biofilm [Text] / S. Rajagopalan,
D. A. Rockstraw, S. Munson-McGee // Bioresource
Technol.-1997 .-Vol.61, N.3.-P.175-183
Quintelas C. Biosorption of Cr(VI) by a Bacillus
coagulans biofilm supported on granular activated carbon
(GAC) [Text]/ C. Quintelas, B. D. Fernandes, J. Castro, et
al. // Chemical Engineering Journal.- 2008 .-Vol.136, N
-3.-P.195-203.
Duc L.H.Bacterial spores as vaccine vehicles
[Text]/L.H. Duc, H.A. Hong, N.Fairweather, et al. // Infect
Immunol.- 2003 .-Vol.71.-P.2810–2818.
Hoa T.T. Fate and dissemination of Bacillus subtilis
spores in a murine model [Text] / T.T. Hoa, L.H. Duc, R.
Isticato, et al. // Appl Environ Microbiol.-2001 .-Vol. 67.-
N 9.- P.3819-3823.
Smirnov V.V. The effect of the complex probiotic
Sporolact on the intestinal microbiocenosis of warmblooded
animals [Text] / V.V. Smirnov, S.R. Reznik,
V.A. V'iunitskaia, et al. // MikrobiolZ.-1995.- Vol.57.-
P.42-49.
Adami A. Occurrence of selected bacteria groups in
the faeces of piglets fed with Bacillus coagulans as probiotic
[Text]/A. Adami, V. Cavazzoni // J Basic Microbiol.-
-Vol.39.-P.3-9.
Donskey C.J. Effect of oral Bacillus coagulans
administration on the density of vancomycin-resistant
enterococci in the stool of colonized mice [Text] /C.J.
Donskey, C.K. Hoyen, S.M. Das, et al. // Letters in Applied
Microbiology.-2001.-Vol.33.-P. 84-88.
Hyronimus B. Coagulin, a bacteriocin - like inhibitory
substance produced by Bacillus coagulans I4 [Text] /
B. Hyronimus, C. Le Marrec, M.C. Urdaci // J Appl Microbiol.-
-Vol.-85, N 1.- P.42-50.
Le Marrec C. Biochemical and genetic characterization
of coagulin, a new antilisterial bacteriocin in the
pediocin family of bacteriocins, produced by Bacillus
coagulans I(4) [Text] / C. Le Marrec, B. Hyronimus, P.
Bressollier et al. // Appl Environ Microbiol.- 2000 .-Vol.-
,N 12 .- P.5213-5220.
Riazi S. Mode of action and safety of lactosporin, a
novel antimicrobial protein produced by Bacillus coagulans
ATCC 7050 [Text] S. Riazi, S. E. Dover, M. L.
Chikindas. // J Appl Microbiol.- 2012.-Vol. 113, N 3.-
P.714-722.
Riazi S. Characterization of lactosporin, a novel
antimicrobial protein produced by Bacillus coagulans
ATCC 7050.[Text] / Riazi S., R. E. Wirawan, V.
Badmaev, et al.// J Appl Microbiol.- 2009.-Vol. 106, N 4.-
P.1370-1377.
Czaczyk K. Antifungal activity of Bacillus coagulans
against Fusarium sp. [Text] / K. Czaczyk, K. Trojanowska,
A. Mueller. // Acta Microbiol Pol.- 2002.-Vol. 51,
N 3 - P.275-283.
Lin S.Y. Effects of supplement with different level
of Bacillus coagulans as probiotics on growth performance
and intestinal microflora populations of broiler
chickens [Text]/ S.Y. Lin, A.T.Y. Hung, J.J. Lu // Journal
of Animal and Veterinary Advances.- 2011.-Vol. 10, N
- P.111-114
. Nyangale E.P. Bacillus coagulans GBI-30, 6086
Modulates Faecalibacterium prausnitzii in Older Men and
Women [Text] / E.P. Nyangale, S. Farmer, H.A. Cash et
al. // J Nutr.- 2015 .-Vol.-145, N 7.-P.1446-1452.
Drago L. Should Lactobacillus sporogenes and
Bacillus coagulans have a future? [Text] / L.Drago,E. De
Vecchi. // J Chemother.- 2009.-Vol. 21,N 4 - P. 371-377.
Babar V. Immunomodulatory activity of Lactobacillus
sporogenes [Text] /V. Babar, R. Thomas, M.
Bhaskar // International Journal of Therapeutic Applications.-
.-Vol.3.- P.32–38.
Ostad S.N. Live and heat-inactivated lactobacilli
from feces inhibit Salmonella typhi and Escherichia coli
adherence to Caco-2 cells [Text] / S.N. Ostad, A.A. Salarian,
M.H. Ghahramani, et al. // Folia Microbiol (Praha).-
- Vol.54.- P.157-160.
Jensen G.S. Ganeden BC30 cell wall and metabolites:
anti-inflammatory and immune modulating effects
in vitro [Text] / G.S. Jensen, K.F. Benson, S.G. Carter,
J.R. Endres // BMC Immunol.- 2010.- Vol.11, N. 15., P.1-
Mandel D.R.Bacillus coagulans: a viable adjunct
therapy for relieving symptoms of rheumatoid arthritis
according to a randomized, controlled trial BMC [Text] /
D.R. Mandel, K. Eichas, J. Holmes // Complementary and
Alternative Medicine.- 2010.-Vol.10.-P.1-12.
Fitzpatrick L.R. Probiotics for the treatment of
Clostridium difficile associated disease [Text] / L.R Fitzpatrick
//World J Gastrointest Pathophysiol.-2013 .-
Vol.4,N 3.- P.47-52.
Surawicz C.M. The search for a better treatment for
recurrent Clostridium difficile disease: use of high-dose
vancomycin combined with Saccharomyces boulardii
[Text] / C.M. Surawicz, L.V. McFarland, R.N. Greenberg,
et al. // Clin Infect Dis.- 2000.-Vol.31.-P.1012–
Fitzpatrick L.R. Bacillus Coagulans GBI-30
(BC30) improves indices of Clostridium difficile-Induced
colitis in mice [Text] / L.R. Fitzpatrick, J.S. Small, W.H.
Greene, et al.// Gut Pathogens.-2011.-Vol.3.-P.16-19.
Flahaut S. Comparison of bile salts and sodium
doceyl sulfate stress responses in Enterococcus faecalis
[Text] / S. Flahaut, J. Frere, P. Boutibonnes, Y. Auffray //
Appl Environ Microbiol.-1996.-Vol. 62.-P.2416–2420.
Fitzpatrick L.R. Bacillus coagulans GBI-30, 6086
limits the recurrence of Clostridium difficile-Induced
colitis following vancomycin withdrawal in mice/ L.R.
Fitzpatrick, J.S. Small, W.H. Greene, et al. // Gut Pathog.-
-Vol. 4,N 1.- P.13-16.
Massot J. Bacterio-pharmacological activity of
Saccharomyces boulardii in clindamycin-induced colitis
in the hamster [Text] / J. Massot, O. Sanchez, R. Couchy,
J. Astoin, A.L. Parodi // Arzneimittelforschung.-1984.-
Vol.34.-P.794–797
Toothaker R.D. Prevention of clindamycin-induced
mortality in hamsters by Saccharomyces boulardii [Text]
/ R.D. Toothaker, G.W. Elmer // Antimicrob Agents
Chemother.- 1984.-Vol. 26.-P.552–556.
Corthier G. Prevention of Clostridium difficile
induced mortality in gnotobiotic mice by Saccharomyces
boulardii [Text] / G. Corthier, F. Dubos, R. Ducluzeau //
Can J Microbiol.- 1986. -Vol.32.-P.894–896.
Martins F.S. Screening of yeasts as probiotic based
on capacities to colonize the gastrointestinal tract and to
protect against enteropathogen challenge in mice [Text] /
F.S. Martins, R.M. Nardi, R.M. Arantes et al. //J Gen
Appl Microbiol.- 2005. -Vol.51.- P.83–92.
Naaber P. Bacterial translocation, intestinal microflora
and morphological changes of intestinal mucosa in
experimental models of Clostridium difficile infection
[Text] / P. Naaber, R.H. Mikelsaar, S. Salminen, M.
Mikelsaar // J Med Microbiol.-1998 -Vol.47.- P.591–598.
Kaur S. Effect of Lactobacillus acidophilus & amp;
epidermal growth factor on experimentally induced Clostridium
difficile infection [Text] / Kaur S., C. Vaishnavi,
K.K. Prasad, et al. // Indian J Med Res.- 2011 -Vol.133.-
P.434–441.
Pillai A. Probiotics for treatment of Clostridium
difficile-associated colitis in adults [Text] /A. Pillai, R.
Nelson // Cochrane Database Syst Rev.- 2008.-
Vol.23:CD004611.
Baron M. Apatented strain of Bacillus coagulans
increased immune response to viral challenge / M. Baron
// Postgrad Med.-2009. -Vol.121.- P.114-118.
Kimmel M. A controlled clinical trial to evaluate
the effect of Ganeden BC30 on immunological markers
[Text]/ M. Kimmel, D. Keller, S. Farmer, D. E. Warrino //
Methods and Findings in Experimental Clinical Pharmacology.-
-Vol.32.- P.129-132.
Lactospore. Режим доступа:
http://www.lactospore.com/about/background-info/
Kodali V.P. Antioxidant and free radical scavenging
activities of an exopolysaccharide from a probiotic bacterium/
V.P. Kodali, R. Sen // Biotechnol J.- 2008.-Vol.3.-
P. 245-251.
Solanki H.K. Evaluation of anti-inflammatory activity
of probiotic on carrageenan-induced paw edema in Wistar
rats [Text]/ H.K. Solanki // Int J Biol Macromol.- 2015 -
Vol.72.- P.1277-1282.
Kumar O.R.M. Feeding of L. sporogenes to rabbits/
O.R.M. Kumar, K.J. Christopher // Ind. Vet. J.- 1989. -
Vol.66.- P.896-898.
Mohan J.C. Short term hypolipidemic effects of oral
Lactobacillus sporogenes therapy in patients with primary
dyslipidemias [Text] / J.C. Mohan, R. Arora, M. Khalilullah
// Indian Heart Journal.- 1990. -Vol.42.- P.361-
Kashyap D. R. Enhanced production of pectinase by
Bacillus sp. DT7 using solid state fermentation [Text] / D.
R.Kashyap, S. K. Soni,R. Tewari // Bioresour Technol.-
-Vol. 88,N. 3.- P.251-254.
Campbell L. L. Folic acid requirement of Bacillus
coagulans[Text] / L. L.Campbell,E. E. Sniff. // J Bacteriol.-
-Vol. 78.- P.267-271.
Marshall R. Growth of Bacillus coagulans in chemically
defined media [Text] / R.Marshall,R. J. Beers. // J
Bacteriol.- 1967.-Vol. 94,N.3.-P. 517-521.
Stover P.I. Physiology of folate and vitamin B12 in
health and disease / P.I. Stover // Nutr Bcv.-2004. -Vol.
(Pt 2).- P.53-55.
Troen A.M. Un metabolized folic acid in plasma is
associated with reduced natural killer cell cytotoxicity
among postmenopausal women [Text] / A.M. Troen, B.
Mitchell, B. Sorensen, el al. // J. Nutr.-2006.-Vol. 1361.-
P.189-94.
Yamaguchi T. Control of immune responses by
antigen-specific regulatory T cells expressing the folate
receptor/T. Yamaguchi, K.Hirota, K. Nagahama, et al.//
Immunity.-2007. -Vol. 271.- P.145-159.
Kunisawa E.A pivotal role of vitamin B9 in the
maintenance of regulatory T cells in vitro and in vivo
[Electronic source] / E.Kunisawa, E. Hashimoto,
I.Ishikawa, H.Kiyono // PLoS ONE.- 2012.-
Vol.72:e32094. doi:l0.137l/journal.pone.0032094
Kinoshita M.Dietary folic acid promotes survival of
Foxp3T regulatory T cells in the colon [Text] /
M.Kinoshita, H.Kayama, T. Kusu et al. // Immunol.-2012.
-Vol.1896.-P.2869-2878.
Le Bourhis L.Mucosal-associated invariant T cells:
unconventional development and function [Text]/L.Le
Bourhis, L. Guerri, M.Dusseaux, et al. // Trends Immunol.-
-Vol.325.-P.212-218.
Kjer-Nielsen L. MRl presents microbial vitamin B
metabolites to MAIT cells [Electronic source]/L. Kjer-
Nielsen, O.Patel, A.I. Corbett, et al. // Nature.-2012.-Vol.
-P. 717-723. doi:l0.1038/natureI1605
La Rosa M. Prevention of antibiotic-associated
diarrhoea with Lactobacillus sporogenes and fructooligosaccharides
in children. A multicenter double-blind
vs. placebo study [Text] / M. La Rosa, G. Bottaro, N.
Gulino et al.// Minerva Pediatrica.-2003.-Vol.55.- P.447-
Majeed M. Bacillus coagulans – probiotic of choice
[Text] / M. Majeed, R. Kamarei // Prebiotics/Probiotics.-
- P.19-21.
Abstracts of papers on the clinical study of Sporlac,
complied by the Sankyo Co., Ltd. Japan
Chandra R. K. Effect of Lactobacillus on the incidence
and severity of acute rotavirus diarrhoea in infants.
A prospective placebo-controlled double-blind study
[Text] / R.K. Chandra // Nutritional Research.-2002.-
Vol.22, N 1.- P.65-69.
Dutta P. Randomised controlled clinical trial of
Lactobacillus sporogenes (Bacillus coagulans), used as
probiotic in clinical practice, on acute watery diarrhoea in
children [Text]/ P. Dutta, U. Mitra, S. Dutta, et al. //
Tropical Medicine and International Health.- 2011.-
Vol.16, N 5.- P.555-561.
Sari F.N. Oral probiotics: Lactobacillus sporogenes
for prevention of necrotizing enterocolitis in very lowbirth
weight infants: a randomized, controlled trial [Text]/
F.N. Sari, E.A. Dizdar, S. Oguz, et al. //European Journal
of Clinical Nutrition. – 2011. – Т. 65. – №. 4. – С.434-
Cui Y.L.Efficacy of Bacillus coagulans tablets in
the treatment of acute and chronic diarrhea [Text] / Y.L.
Cui, F.C. Wan, D.L. Tang, S.H.Wu // Int J Immunotherapy.-
- Vol.20, N 1.- P.17-22.
Hun L. Bacillus coagulans significantly improved
abdominal pain and bloating in patients with IBS [Text]/
L. Hun // Postgrad Med.-2009.- Vol.121.- P. 119-24
Dolin B.J. Effects of a proprietary Bacillus coagulans
preparation on symptoms of diarrhea-predominant
irritable bowel syndrome/ B. J. Dolin // Methods Find
Exp Clin Pharmacol.- 2009.- Vol.31, N 10.-P.655-659
Rogha M. The efficacy of a symbiotic containing
Bacillus Coagulans in treatment of irritable bowel syndrome:
a randomized placebo-controlled trial [Text] / M.
Rogha, M. Z. Esfahani,A. H. Zargarzadeh// Gastroenterology
and hepatology from bed to bench.- 2014.-Vol.7,
N3- P.-156-163.
Keller D. Bacillus coagulans as a probiotic [Text]/
D. Keller, S. Farmer, A. McCartney, G. Gibson // Food
Science and Technology Bulletin: Functional Foods.-
- Vol.7, N 7.- P.103–109.
Mohan J.C. Preliminary observations on effect of
Lactobacillus sporogenes on serum lipid levels in hypercholesterolemic
patients [Text]/ J.C. Mohan, R. Arora,
M. Khalilullah // Indian Journal of Medical Research.-
-Vol.92.- P.431-432
Agosta C., Atlante M., Benvenuti C. Randomized
controlled study on clinical efficacy of isoflavones plus
Lactobacillus sporogenes, associated or not with a natural
anxiolytic agent in menopause/ C. Agosta, M. Atlante, C.
Benvenuti // Minerva Ginecol.- 2011.- Vol.63, N 1.- P.11-
Benvenuti C., Setnikar I. Effect of Lactobacillus
sporogenes on oral isoflavones bioavailability: single dose
pharmacokinetic study in menopausal women [Text] / C.
Benvenuti, I. Setnikar // Arzneimittel-forschung.-2011.-
Vol.61, N 11.- P.605-609
Palacios S. Women's perception of the efficacy of a
soy extract with probiotic: the M3 study [Text] /
S.Palacios, I. A. Rojo, M. J. Cancelo, et al. // Gynecol
Endocrinol.- 2008.-Vol. 24, N4.– P.-178-183
Voichishina L.G. The use of sporulating bacteria in
treating patients with dysbacteriosis [Text] / L.G.
Voichishina, V.A. Chaplinskii, V.A.V'iunitskaia // Vrach
Delo- 1991.- Vol.12.- P. 73-75.
Mathur S.N. Sporlac therapy in treatment of aphthous
stomatitis [Text] / S.N. Mathur // Uttar Pradesh
State Dent J.- 1970.-Vol. 11.- P. 7-12.
Sharma J.K. Clinical trial of Sporlac in the treatment
of recurrent aphthous ulceration [Text] / J.K. Sharma,
K.K. Kapoor, R.D. Mukhija // Uttar Pradesh State
Dent J.- 1980.-Vol.11.- P.7-12.
Jindal G. A comparative evaluation of probiotics on
salivary mutans streptococci counts in Indian children
[Text] / G. Jindal, R.K. Pandey, J. Agarwal, M. Singh //
Eur Arch Paediatr Dent.- 2011.-Vol. 12.- P.211-215.
Shirodkar N.V. Multi-centre clinical assessment of
Myconip vaginal tablets in non-specific vaginitis [Text] /
N.V. Shirodkar, P.C. Sankholkar, S. Ghosh, S.M. Nulkar
// Indian Pract.- 1980.-Vol.33.- P.207-210.
Sanders M.E. Sporeformers as Human Probiotics:
Bacillus, Sporolactobacillus, and Brevibacillus [Text] /
M.E. Sanders, L. Morelli, T.A. Tompkins // Comprehensive
Reviews in Food Science and Food Safety.- 2003.-
Vol.2, N.3.- P.101
Mandel D.R., Eichas K., Holmes J. Bacillus coagulans:
a viable adjunct therapy for relieving symptoms of
rheumatoid arthritis according to a randomized, controlled
trial [Text] / D.R. Mandel, K. Eichas, J. Holmes // BMC
Complement Altern Aferf.-2010.-Vol.10.- P. l.
Endres, J. R. Safety assessment of a proprietarypreparation
of a novel probiotic, Bacillus coagulans,
as a food ingredient [Text] / J. R.Endres, A.Clewell, K.
A.Jade, et al.// Food Chemistry and Toxicology.-2009. -
Vol. 47, N 6.-P.1231- 1238.
Abhari Kh.The effects of probiotic, prebiotic and
synbiotic diets containing Bacillus coagulans and inulin
on rat intestinal microbiota [Text] / Abhari Kh., Shekarforoush
S.S., Sajedianfard J., Hosseinzadeh S., Nazifi S. //
IJVR. – 2015. – 16, N3. – Р. 267-273.
Gu Sh.B. Potential probiotic attributes of a new
strain of Bacillus coagulans CGMCC 9951 isolated from
healthy piglet feces [Text] / Sh.B.Gu, L.N.Zhao, Y.Wu, et
al.// World J. Microbiol. Biotechnol. – 2015. – 31, N6. –
Р.851-863.
Ratna Sudha M. Clinical Study of Bacillus coagulans
Unique IS-2 (ATCC PTA-11748) in the Treatment of
Patients with Bacterial Vaginosis [Text] / M.Ratna Sudha,
K.A.Yelikar, S. Deshpande // Indian J Microbiol. – 2012.
– 52, N3. – Р.396-399.
Dutta Ph.Randomised controlled clinical trial of
Lactobacillus sporogenes(Bacillus coagulans), used as
probiotic in clinical practice, on acute watery diarrhoea in
children [Text] / Dutta Ph., Mitra U., Dutta Sh., et al. //
Trop. Med. Int. Health. – 2011. – 16, N5. – Р.555-561.
Cano Roca C.L. Characterization of Commercial
Probiotics: Antibiotic Resistance, Acid and Bile Resistance,
and Prebiotic Utilization [Text] / C.L. Cano
Roca // Dissertations & Theses in Food Science and
Technology. – 2014. – 46 р.
Spinosa M.R.The trouble in tracing opportunistic
pathogens: cholangitis due to Bacillus in a French hospital
caused by a strain related to an Italian probiotic? [Text] /
M.R.Spinosa, F.Wallet, R.J.Courcol, M.R. Oggioni //
Microbial Ecology in Health and Disease. – 2000. – Vol.
– Р.99-101.
De Clerck E. Genotypic diversity among Bacillus
licheniformis strains from various sources [Text] / E.De
Clerck, P.De Vos // FEMS Microbiol Lett. – 2004. – Vol.
– Р.91-98.
Attachment I final risk assessment of Bacillus licheniformis
// Режим доступа:
http://www.epa.gov/sites/production/files/2015-
/documents/fra005.pdf. - 1997.
Glushanova N.A. Biological properties of lactobacilles
[Text] /N.A. Glushanova // Bull.sib med – 2003. –
N4. – P.50-58.
Downloads
How to Cite
Issue
Section
License
Copyright (c) 2020 Annals of Mechnikov's Institute
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
